Deal data, CRC developments, and the unglamorous prep work that separates a full-price sale from a discount — written by a broker who has spent four decades doing New Jersey transactions.
New Jersey's social equity excise fee has sat at $2.50 an ounce while the statutory ceiling for its price tier is $30 — and the tier table gets more permissive as cannabis gets cheaper. The CRC reopens the question on October 29.
Read the analysis →
Florida's 2026 adult-use ballot question died about 47,000 signatures short, and Pennsylvania's legalization bill has sat in a Senate committee since May 2025. New Jersey has 272 open dispensaries, 358 towns that want nothing to do with them, and a two-year ownership lockout most out-of-state buyers have never heard of.
Read the analysis →
New Jersey flower has fallen from about $12.49 a gram to $8.09, and the cheapest remaining lever is getting existing customers back more often. But the loyalty program that does it answers to four separate rulebooks, and only one of them comes from the CRC.
Read the analysis →
A buyer's accountant spends about six hours with your file before deciding what your store is worth to them, and they are not reading your P&L. They are testing whether Metrc, your POS, your bank deposits and your filed returns tell the same story.
Read the analysis →
A standard conditional cannabis application in New Jersey costs $200 to submit and $800 on approval. The license is the cheapest part of the whole thing - here is what each of the six classes actually permits, and what each one is worth when it changes hands.
Read the analysis →
New Jersey stores sold 2.5 percent more units in August 2026 than a year earlier and still booked 2.8 percent less revenue. That gap is price compression, and four numbers already sitting in your POS decide whether you fight it or absorb it.
Read the analysis →
The SBA is closed to cannabis, SAFE Banking is still a bill, and institutional cannabis credit is pricing near 16 percent. That leaves the seller as the lender - here is how to carry paper without carrying all of the risk.
Read the analysis →
In July, TerrAscend paid roughly $9 million for a single dispensary in Flemington. Three months later, another New Jersey operator's collateral is headed to an Article 9 foreclosure sale - same state, same license rules, opposite outcomes.
Read the analysis →Whether you are thinking about selling, or looking to buy into the New Jersey market from out of state, the first conversation costs nothing and stays between us.
If you just want to know the number, I will tell you the number.